BS_769BDPDB
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 251.14980289093296
- age_years
- 4.186
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_E4GC9EXR | Ganglioglioma | — | 0.972 |
| 2 | s_150203_1a | EPN | Posterior Fossa EPN | 0.969 |
| 3 | BS_D3YBV7KB | low-grade glioma | — | 0.967 |
| 4 | BS_55JW3HFM | Ganglioglioma | — | 0.958 |
| 5 | BS_JH29M4KG | pilocytic astrocytoma | — | 0.951 |
| 6 | SRR1455369 | GTEX | — | 0.951 |
| 7 | SJEPD009_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.951 |
| 8 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.951 |
| 9 | BS_24AHZ9ZW | low-grade glioma | — | 0.950 |
| 10 | BS_W7FP2G3F | DNET | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.683 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.675 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.669 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.657 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.641 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.635 | Idelalisib | — uncovered |
| COAGULATION | 0.548 | Binimetinib | — uncovered |
| COMPLEMENT | 0.519 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.513 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.501 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.491 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.451 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.446 | Inavolisib | — uncovered |
| APOPTOSIS | 0.442 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.432 | Inavolisib | — uncovered |
| HYPOXIA | 0.419 | Idelalisib | — uncovered |
| MYOGENESIS | 0.372 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.364 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.357 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.339 | Inavolisib | — uncovered |